Skip to main content
SpringerLink
Log in

Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The effect of pretreatment with antitumor drugs on lymphokine-activated killer (LAK) cell cytotoxic activity, determined by lactate-dehydrogenase(LDH)-release assay, was investigated. LAK cells were induced by incubating peripheral blood lymphocytes of healthy donors in medium containing interleukin-2 (IL-2) and monoclonal anti-CD3 antibody for 6–7 days. A human lung squamous carcinoma cell line, SQ-5, was used as an adherent target. After 24 h exposure of the target cells to cisplatin, doxorubicin, or mitomycin C, the drugs were washed off and LAK cells were added at an E/T ratio of 5. During further incubation for 48 h, LDH release from cisplatin- or doxorubicin-pretreated target cells was markedly higher than that from non-pretreated target cells. The combination of cisplatin and LAK cells has an additive cytotoxic effect and that of mitomycin C and LAK cells does not; there may also be an additive effect late in the toxicity mechanism between doxorubicin and LAK cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Acosta D, Anuford DC, Smith RV (1980) Cytotoxicity of acetaminophen and papaverine in primary cultures of rat hepatocytes. Toxicol Appl Pharmacol 53: 306

    PubMed  Google Scholar 

  2. Allavena P, Grandi M, D'Incalci M, Geri O, Giuliani FC, Mantovani A (1987) Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes. Int J Cancer 40: 104

    PubMed  Google Scholar 

  3. Carmicael J, Degraff WG, Gazdar AF, Minna JD, Mitchel JB (1987) Evaluation of the tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936

    PubMed  Google Scholar 

  4. Decker T, Matthes ML (1988) A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 15: 61

    Google Scholar 

  5. Grimm EA, Mazunder A, Zhang HZ, Rosenberg SA (1983) Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 157: 884

    PubMed  Google Scholar 

  6. Harker WG, Tom C, McGregor JR, Slade L, Samlowski WE (1990) Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell mediated cytolysis. Cancer Res 50: 5931

    PubMed  Google Scholar 

  7. Heo DS, Park JG, Hata K, Day R, Herberman RB, Whiteside TL (1990) Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor-cytotoxicity. Cancer Res 50: 3681

    PubMed  Google Scholar 

  8. Korzeniewski C, Callewaert DM (1983) An enzyme-release assay for natural cytotoxicity. J Immunol Methods 64: 313

    PubMed  Google Scholar 

  9. Leroux JY, Mercier G, Oth D (1986) Enhancement of murine lymphoma cell lysability by CTL and by LAK cells, after treatments with mitomycin C and with Adriamycin. Int J Immunopharmacol 8: 369

    PubMed  Google Scholar 

  10. Papa MZ, Yang JC, Vetto JT, Shiloni E, Eisenthal A, Rosenberg SA (1988) Combined effect of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumor. Cancer Res 48: 122

    PubMed  Google Scholar 

  11. Passerini CG, Radrizzani M, Erba E, Fossati G, Parmiani G (1987) Lysis by lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide. Cancer Res 47: 2547

    PubMed  Google Scholar 

  12. Passerini CG, Rivoltini L, Supino R, Rodolfo M, Radrizzani M, Fossati G, Parmiani G (1988) Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes. Cancer Res 48: 2372

    PubMed  Google Scholar 

  13. Roper PR, Drewinko B (1976) Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 36: 2182

    PubMed  Google Scholar 

  14. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skiber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485

    PubMed  Google Scholar 

  15. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan M, Robertson GN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889

    PubMed  Google Scholar 

  16. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474

    PubMed  Google Scholar 

  17. Salup RR, Wiltrout RH (1986) Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes. Cancer Res 46: 3358

    PubMed  Google Scholar 

  18. Scuderi P, Woo L, Chong AS, Liu R, Salmon SE (1990) Modification of the clonogenic assay for the detection of the lymphokine activated killer cell activity. J Immunol Methods 128: 119

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. RIKEN Cell Bank, The Institute of Physical and Chemical Research (RIKEN), 3-1-1 Koyadai, 305, Tsukuba Science City, Ibaraki, Japan

    Koji Kawai, Tetsuji Sasaki, Kaoru Saijo-Kurita & Tadao Ohno

  2. Department of Urology, Tsukuba University Hospital, 1-1-1 Tennoudai, 305, Tsukuba Science City, Ibaraki, Japan

    Koji Kawai, Hideyuki Akaza & Kenkichi Koiso

  3. Kyokuto Pharmaceutical Industries Co. Ltd., 3333-26, Aza-Asayama, Ooaza-Kamitezuna, Takahagi-shi, Ibaraki, Japan

    Tetsuji Sasaki

Authors
  1. Koji Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuji Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kaoru Saijo-Kurita
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideyuki Akaza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenkichi Koiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tadao Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kawai, K., Sasaki, T., Saijo-Kurita, K. et al. Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay. Cancer Immunol Immunother 35, 225–229 (1992). https://doi.org/10.1007/BF01789327

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01789327

Key words

Search

Navigation